Navigation Links
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Date:8/8/2013

WOODCLIFF LAKE, N.J., Aug. 8, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell lymphoma (CTCL).  E7777 is designed to have an improved purity profile and manufacturing process. It is currently in a pivotal trial intended to support its submission for approval.

The Orphan Drug Act (ODA) allows FDA to grant orphan status to a drug which has the potential for the treatment, diagnosis, or prevention of a rare disease/disorder that affects fewer than 200,000 people in the United States.

CTCL is a rare type of cancer that begins in the white blood cells and attacks the skin. It is one of several types of lymphoma collectively called non-Hodgkin lymphoma.

Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Media InquiriesInvestor InquiriesLaurie Landau

Alex Scott Eisai Inc.

Eisai Inc.201-746-2510

201-746-2177


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
2. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Agnitio Grants 10,000 New Licenses Globally this Financial Year
4. FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
5. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
6. Cardinal Health Foundation Invites Local Non-profit Organizations To Apply For Grants To Prevent Prescription Drug Abuse
7. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
8. FDA Grants Chimerix Fast Track Designation for CMX001 for the Prevention of Clinically Significant Cytomegalovirus Infection
9. Pancreatic Cancer Action Network Opposes Sequestration Cuts To National Institutes Of Health & Cancer Research Grants
10. State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
11. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Mich. , April 28, 2016   ... . Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... has signed a definitive agreement to acquire Valley ... Specialty Pharmacy ("TNH"), a leading specialty pharmacy that ... Van Nuys, California . In 2015, TNH ...
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
(Date:4/28/2016)... , April 28, 2016 ... , George Phillips und ... Unternehmens    ArisGlobal®, ein führender ... Sciences, gab heute bekannt, dass neue Führungskräfte ... Unternehmens gestoßen sind, die vielfältige Erfahrungen mitbringen. ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... East Los Angeles ... extractions. Currently, patients can visit Dr. Assili to receive any dental extraction treatment for ... and it expires June 30, 2016. With the lower price, patients can more easily ...
(Date:5/2/2016)... ... 2016 , ... Further establishing itself as a leader in natural pet products ... Boxes were selected from over 1,000 entrants as a winner and recipient of the ... chews for dogs are a favorite product among pet-parents worldwide, as each whimsical knobby ...
(Date:5/2/2016)... ... 2016 , ... Visceral fat, also known as “deep fat” ... and pancreas. If not properly addressed, visceral fat can lead to serious health ... Oncology and Palliative Care, warns against the dangers of visceral fat. “Just because ...
(Date:5/2/2016)... ... ... According to an American Psychological Association article, the Centers for ... age of 18. Of those who survive, many still face effects as they reach ... her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from women who ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a ... designed to automate and improve the rapid diagnosis, triage and admission of patients ... platform, application, and mobile experience for the first time at GENBAND’s Perspectives16 conference. ...
Breaking Medicine News(10 mins):